Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University
• Collaborator: Autism Speaks
• Treatments: Mecamylamine

Criteria

Inclusion Criteria:

• Autistic Disorder or Pervasive Developmental Disorder-Not Otherwise Specified

• Age 4-12

• General good health

• IQ of >=36 or mental age of >=18 months

• Parent/caregiver willingness to accompany child to clinic and monitor for side effects

Exclusion Criteria:

• Unstable Seizure Disorder

• Psychoactive medication in the process of adjustment

• Antipsychotic medication in previous 3 months before baseline

• Systemic corticoids (inhalers allowed)

• Planned beginning of major behavioral intervention in 3 months of study or the 2 months prior to the study.